CSL Reports 5-Year Efficacy of HEMGENIX, 94% of Patients Free from Continuous Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 11 hour ago0mins
- Durable Efficacy: In the HOPE-B study, 94% of patients remained free from continuous prophylaxis treatment for five years following a single infusion of HEMGENIX, demonstrating the therapy's long-term effectiveness and significant improvement in patients' quality of life.
- Stable Factor IX Activity: Five years post-treatment, the mean factor IX activity level was sustained at 36.1%, indicating HEMGENIX's ability to provide effective bleed protection over time, reducing patients' reliance on conventional therapies.
- Significant Bleeding Rate Reduction: The annualized bleeding rate dropped from a baseline of 4.16 to 0.40, with joint bleeds reduced by 93% and spontaneous bleeds by 94%, which not only alleviates the physical burden on patients but may also lower healthcare costs.
- Favorable Safety Profile: Over five years of follow-up, no serious adverse events related to HEMGENIX were reported, highlighting the therapy's safety and enhancing its market acceptance and potential for future expansion.
CSL.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on CSL
Wall Street analysts forecast CSL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSL is 382.67 USD with a low forecast of 356.00 USD and a high forecast of 400.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 322.800
Low
356.00
Averages
382.67
High
400.00
Current: 322.800
Low
356.00
Averages
382.67
High
400.00
JPMorgan
Overweight
downgrade
$410 -> $400
2025-10-30
Reason
JPMorgan
Price Target
$410 -> $400
2025-10-30
downgrade
Overweight
Reason
JPMorgan lowered the firm's price target on Carlisle to $400 from $410 and keeps an Overweight rating on the shares. The firm updated the company's model post the Q3 report.
Truist
Keith Hughes
Hold
downgrade
$350 -> $340
2025-10-30
Reason
Truist
Keith Hughes
Price Target
$350 -> $340
2025-10-30
downgrade
Hold
Reason
Truist analyst Keith Hughes lowered the firm's price target on Carlisle to $340 from $350 and keeps a Hold rating on the shares. The company had put some cautionary language about business in a conference presentation last month that brought down estimates, and while its Q3 results came in above views, its Q4 guide was a good bit below and will result in the second half estimates falling notably, the analyst tells investors in a research note.
Vertical Research
Adam Baumgarten
initiated
$356
2025-10-20
Reason
Vertical Research
Adam Baumgarten
Price Target
$356
2025-10-20
initiated
Reason
Vertical Research analyst Adam Baumgarten initiated coverage of Carlisle with a Hold rating and $356 price target.
Truist
Keith Hughes
Hold
downgrade
$380 -> $350
2025-09-22
Reason
Truist
Keith Hughes
Price Target
$380 -> $350
2025-09-22
downgrade
Hold
Reason
Truist analyst Keith Hughes lowered the firm's price target on Carlisle to $350 from $380 and keeps a Hold rating on the shares. Negative commentary on markets and changes in distribution ownership discussed in the company's slides at a recent investor conference has raised questions on near-term results, the analyst tells investors in a research note. Investors will likely at least stay away from the shares until this situation is cleared up with potential for more downside pressure, the firm added.
See All Ratings
About CSL
Carlisle Companies Incorporated is a manufacturer and supplier of building envelope products and solutions that enable energy efficiency in buildings. Its segments include Carlisle Construction Materials (CCM) and Carlisle Weatherproofing Technologies (CWT). The CCM segment produces a complete line of energy-efficient single-ply roofing products and warranted roof systems and accessories for the commercial building industry, including ethylene propylene diene monomer (EPDM), thermoplastic polyolefin (TPO) and polyvinyl chloride (PVC) membrane, polyisocyanurate (polyiso) insulation, and engineered metal roofing and wall panel systems for commercial and residential buildings. CWT segment produces building envelope solutions that drive energy efficiency and sustainability in commercial and residential applications. Its products include waterproofing and moisture protection products, protective roofing underlayments, fully integrated liquid and sheet applied air/vapor barriers and others.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?